|Bid||0.0000 x 800|
|Ask||0.0000 x 1200|
|Day's Range||2.7900 - 2.9894|
|52 Week Range||2.6400 - 10.9200|
|Beta (5Y Monthly)||0.29|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.00|
LEXINGTON, Mass., January 04, 2022--Concert completed patient enrollment in the CTP-543 THRIVE-AA2 Phase 3 trial for alopecia areata.
LEXINGTON, Mass., January 03, 2022--Concert to Participate in the H.C. Wainwright BIOCONNECT Conference.
Every investor in Concert Pharmaceuticals, Inc. ( NASDAQ:CNCE ) should be aware of the most powerful shareholder...